105 related articles for article (PubMed ID: 24065329)
1. The quad pill, a once-daily combination therapy for HIV infection.
Johnson LB; Saravolatz LD
Clin Infect Dis; 2014 Jan; 58(1):93-8. PubMed ID: 24065329
[TBL] [Abstract][Full Text] [Related]
2. Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens.
Mayer KH; Jones D; Oldenburg C; Jain S; Gelman M; Zaslow S; Grasso C; Mimiaga MJ
J Acquir Immune Defic Syndr; 2017 Aug; 75(5):535-539. PubMed ID: 28696345
[TBL] [Abstract][Full Text] [Related]
3. Strength in Amalgamation: Newer Combination Agents for HIV and Implications for Practice.
McCoy C; Badowski M; Sherman E; Crutchley R; Smith E; Chastain DB;
Pharmacotherapy; 2018 Jan; 38(1):86-107. PubMed ID: 29105160
[TBL] [Abstract][Full Text] [Related]
4. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment.
Olin JL; Spooner LM; Klibanov OM
Ann Pharmacother; 2012 Dec; 46(12):1671-7. PubMed ID: 23136357
[TBL] [Abstract][Full Text] [Related]
5. Elvitegravir: a once-daily inhibitor of HIV-1 integrase.
Wills T; Vega V
Expert Opin Investig Drugs; 2012 Mar; 21(3):395-401. PubMed ID: 22321026
[TBL] [Abstract][Full Text] [Related]
6. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
Gallant JE; Koenig E; Andrade-Villanueva J; Chetchotisakd P; DeJesus E; Antunes F; Arastéh K; Moyle G; Rizzardini G; Fehr J; Liu Y; Zhong L; Callebaut C; Szwarcberg J; Rhee MS; Cheng AK
J Infect Dis; 2013 Jul; 208(1):32-9. PubMed ID: 23532097
[TBL] [Abstract][Full Text] [Related]
7. Cobicistat: a new boost for the treatment of human immunodeficiency virus infection.
Shah BM; Schafer JJ; Priano J; Squires KE
Pharmacotherapy; 2013 Oct; 33(10):1107-16. PubMed ID: 23471741
[TBL] [Abstract][Full Text] [Related]
8. A 68-year old male presenting with rhabdomyolysis-associated acute kidney injury following concomitant use of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate and pravastatin/fenofibrate: a case report.
Suttels V; Florence E; Leys J; Vekemans M; Van den Ende J; Vlieghe E; Kenyon C
J Med Case Rep; 2015 Sep; 9():190. PubMed ID: 26347243
[TBL] [Abstract][Full Text] [Related]
9. Advances in antiretroviral therapy.
Arribas JR; Eron J
Curr Opin HIV AIDS; 2013 Jul; 8(4):341-9. PubMed ID: 23666392
[TBL] [Abstract][Full Text] [Related]
10. Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence.
McAllister J; Read P; McNulty A; Tong WW; Ingersoll A; Carr A
HIV Med; 2014 Jan; 15(1):13-22. PubMed ID: 24007390
[TBL] [Abstract][Full Text] [Related]
11. Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine.
Crauwels H; van Heeswijk RP; Stevens M; Buelens A; Vanveggel S; Boven K; Hoetelmans R
AIDS Rev; 2013; 15(2):87-101. PubMed ID: 23681436
[TBL] [Abstract][Full Text] [Related]
12. Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone.
Muñoz de Benito RM; Arribas López JR
Expert Rev Anti Infect Ther; 2006 Aug; 4(4):523-35. PubMed ID: 17009933
[TBL] [Abstract][Full Text] [Related]
13. Elvitegravir for the treatment of HIV.
Unger NR; Worley MV; Kisgen JJ; Sherman EM; Childs-Kean LM
Expert Opin Pharmacother; 2016 Dec; 17(17):2359-2370. PubMed ID: 27767362
[TBL] [Abstract][Full Text] [Related]
14. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
15. Cobicistat, a pharmacoenhancer for HIV treatments.
Temesgen Z
Drugs Today (Barc); 2013 Apr; 49(4):233-7. PubMed ID: 23616950
[TBL] [Abstract][Full Text] [Related]
16. Anti-HIV drugs.
De Clercq E
Verh K Acad Geneeskd Belg; 2007; 69(2):81-104. PubMed ID: 17550060
[TBL] [Abstract][Full Text] [Related]
17. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
Marcelin AG; Charpentier C; Wirden M; Landman R; Valantin MA; Simon A; Katlama C; Yeni P; Descamps D; Aubron-Olivier C; Calvez V
J Antimicrob Chemother; 2012 Jun; 67(6):1475-8. PubMed ID: 22371439
[TBL] [Abstract][Full Text] [Related]
18. Cobicistat: Review of a Pharmacokinetic Enhancer for HIV Infection.
Sherman EM; Worley MV; Unger NR; Gauthier TP; Schafer JJ
Clin Ther; 2015 Sep; 37(9):1876-93. PubMed ID: 26319088
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.
Rockstroh JK; Lennox JL; Dejesus E; Saag MS; Lazzarin A; Wan H; Walker ML; Xu X; Zhao J; Teppler H; Dinubile MJ; Rodgers AJ; Nguyen BY; Leavitt R; Sklar P;
Clin Infect Dis; 2011 Oct; 53(8):807-16. PubMed ID: 21921224
[TBL] [Abstract][Full Text] [Related]
20. Raltegravir: the first HIV type 1 integrase inhibitor.
Hicks C; Gulick RM
Clin Infect Dis; 2009 Apr; 48(7):931-9. PubMed ID: 19231980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
